Novo Nordisk, the company that manufactures Wegovy and Ozempic, funded both trials.
“If you could say, ‘Well, actually, it doesn’t,’ that’s big.”The higher the dose of oral semaglutide, the more side effects seem to come with it.
In the trial of people who were overweight or obese, 80 percent of those who took oral semaglutide reported gastrointestinal issues like vomiting, nausea, constipation or diarrhea.
Pfizer has also tested its own pill in that drug class.
Oral semaglutide is not new: There’s already a tablet form of the compound on the market, sold under the name Rybelsus.
Persons:
“, ”, Robert Gabbay, ’, Eli Lilly, Andrew Kraftson
Organizations:
Novo Nordisk, American Diabetes Association, New England, of Medicine, Pfizer, Drug Administration, Michigan Medicine
Locations:
Wegovy